191 related articles for article (PubMed ID: 38103190)
1. Subcellular localization of PD-L1 and cell-cycle-dependent expression of nuclear PD-L1 variants: implications for head and neck cancer cell functions and therapeutic efficacy.
Schulz D; Feulner L; Santos Rubenich D; Heimer S; Rohrmüller S; Reinders Y; Falchetti M; Wetzel M; Braganhol E; Lummertz da Rocha E; Schäfer N; Stöckl S; Brockhoff G; Wege AK; Fritsch J; Pohl F; Reichert TE; Ettl T; Bauer RJ
Mol Oncol; 2024 Feb; 18(2):431-452. PubMed ID: 38103190
[TBL] [Abstract][Full Text] [Related]
2. Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma.
Schulz D; Streller M; Piendl G; Brockhoff G; Reichert TE; Menevse AN; Beckhove P; Hautmann MG; Bauer RJ; Ettl T
Carcinogenesis; 2020 Jul; 41(7):984-992. PubMed ID: 31637423
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
[TBL] [Abstract][Full Text] [Related]
4. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor-intrinsic PD-L1 suppresses the progression and aggressiveness of head and neck cancer by inhibiting GSK3β-dependent Snail degradation.
Ahn CH; Oh KY; Jin B; Lee WW; Kim J; Kim HJ; Park DG; Swarup N; Chawla K; Ryu MH; Kim UK; Choi SJ; Yoon HJ; Hong SD; Shin JA; Cho SD
Cell Oncol (Dordr); 2023 Apr; 46(2):267-282. PubMed ID: 36441378
[TBL] [Abstract][Full Text] [Related]
6. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma.
Mann JE; Smith JD; Kulkarni A; Foltin SK; Scheftz EB; Murray IR; Gensterblum-Miller E; Brummel CV; Bhangale A; Hoesli RC; Brenner JC
Oral Oncol; 2023 Nov; 146():106562. PubMed ID: 37666053
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells.
Eichberger J; Schulz D; Pscheidl K; Fiedler M; Reichert TE; Bauer RJ; Ettl T
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138288
[TBL] [Abstract][Full Text] [Related]
10. E3 Ubiquitin Ligase RNF125 Suppresses Immune Escape in Head and Neck Squamous Cell Carcinoma by Regulating PD-L1 Expression.
Jiang C; He L; Xiao S; Wu W; Zhao Q; Liu F
Mol Biotechnol; 2023 Jun; 65(6):891-903. PubMed ID: 36344734
[TBL] [Abstract][Full Text] [Related]
11. Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma.
Schulz D; Wetzel M; Eichberger J; Piendl G; Brockhoff G; Wege AK; Reichert TE; Ettl T; Bauer RJ
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884892
[TBL] [Abstract][Full Text] [Related]
12. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Chen SW; Li SH; Shi DB; Jiang WM; Song M; Yang AK; Li YD; Bei JX; Chen WK; Zhang Q
Int J Biol Markers; 2019 Dec; 34(4):398-405. PubMed ID: 31674884
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
14. The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.
Nieto C; Miller B; Alzofon N; Chimed T; Himes J; Joshi M; Gomez K; Chowdhury FN; Le PN; Weaver A; Somerset H; Morton JJ; Wang JH; Wang XJ; Gao D; Hansen K; Keysar SB; Jimeno A
J Natl Cancer Inst; 2023 Nov; 115(11):1392-1403. PubMed ID: 37389416
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
16. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
18. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
19. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer.
Idel C; Ribbat-Idel J; VON Bernuth A; Fleckner J; Rades D; Kirfel J; Sailer V; Plötze-Martin K; Bruchhage KL; Pries R
Anticancer Res; 2023 Dec; 43(12):5349-5358. PubMed ID: 38030173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
